NervGen Pharma Corp.

Recent News

  • NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)

    Panel discussion will focus on the successful translation of NervGen's lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James GuestNervGen will also present at the International Investment Forum Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will...

    2022-05-16 8:30 AM EDT
  • NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results

    Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing...

    2022-05-12 8:30 AM EDT
  • NervGen Pharma Appoints Craig Thompson to the Board of Directors

    30 years of industry experience from CEO of Nasdaq-listed biotech to Vice President, Marketing at PfizerExperience on 16 development stage products, 15 commercial stage products and numerous pre-clinical assets, in both start-up and large pharmaceutical companiesVancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company developing a first-in-class neuroreparative drug to treat nervous system damage, today announced the appointment of Craig Thompson to NervGen's Board...

    2022-04-13 8:30 AM EDT
  • NervGen Pharma Grants Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - April 6, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 376,000 incentive stock options to Employees and Officers exercisable at a price of $2.06 per share for a period of 10 years and that vest equally every six months over a two-year period. All options have been...

    2022-04-06 5:45 PM EDT
  • NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting

    Human subjects now being enrolled in the second cohort of multiple ascending dose portion of the studyNVG-291 dose administered in the first cohort is already above the highest corresponding dose found to be efficacious in animal models and is substantially higher than the lower effective doses where dramatic functional improvements were observedVancouver, British Columbia--(Newsfile Corp. - March 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a...

    2022-03-31 8:30 AM EDT
  • NervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim Group

    Vancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the 2022 Virtual Growth Conference presented by Maxim Group, being held virtually on March 28-30, 2022.Paul Brennan, NervGen's President and CEO, will provide an overview of the Company's operations and the development plans for its lead compound, NVG-291. The...

    2022-03-23 8:30 AM EDT
  • NervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291

    The dose of NVG-291 in the first cohort is already above the highest corresponding dose that resulted in dramatic functional improvements in animal modelsApproval moves NervGen one step closer to Phase 1b/2 efficacy studies in Alzheimer's disease, multiple sclerosis and spinal cord injury patients later in 2022NervGen's proprietary NVG-291, has been demonstrated in preclinical studies to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination and plasticityVancouver, British Columbia--(Newsfile Corp. - March 15, 2022) - NervGen Pharma Corp....

    2022-03-15 8:30 AM EDT
  • NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Study

    Vancouver, British Columbia--(Newsfile Corp. - February 28, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2021."We have continued to make important progress in our Phase 1 clinical trial with NVG-291 in the fourth quarter of 2021 and early 2022," stated Paul Brennan, NervGen's President & CEO....

    2022-02-28 8:30 AM EST